Information for researchers

Information for applicants


The IGA operates response mode research funding and has an annual awards cycle inviting applications for research grants. It will consider applications for clinical and laboratory-based research projects into the causes and prevention, early detection, diagnosis, treatment or improving the quality of life of people of all ages living with glaucoma and allied conditions.

Q: How much is available?

A:  Grant funding is dependent on the IGA’s charitable income, so varies year to year. The awards schedule is determined annually in June and published on the IGA website in July or August.

Q: what costs are eligible?

A: Eligible costs include:

  • staff costs, administrative support
  • capital items (items over £2,500 require three written quotes once an award is agreed), consumables
  • open access publication
  • computing / data analysis
  • reasonable travel, communication and dissemination costs

 Ineligible costs include:

  • non-project related expenses
  • annual leave / sick leave/ parental leave costs
  • parking or travel to the general place of work
  • institutional overheads

Q: How are decisions made?

A: Grants are awarded in open competition by an awards panel. The Chair of the IGA’s Clinical Advisory Panel (CAP) (currently Nicholas Strouthidis) will determine the membership and procedures for each awards panel, in consultation with any other organisations involved in administering the grants.

Panels will usually include at least one lay member. The awards panel will ensure all award applications are assessed against objective criteria in keeping with the objectives of the award.

Peer review processes will vary according to the size and type of the grant, the degree of in-house expertise, and the funding mechanism, but the usual process will be for applications to be sent for at least one, but preferably two external peer reviews.

Q: What are the grant making criteria?

A: Grants will be awarded on the basis of:

  • scientific content
  • likelihood of a conclusive outcome of the proposed study
  • likely impact of the research on patient care or appropriate scientific

advance or understanding of glaucoma

  • location in a suitable institution
  • presentation
  • value for money
  • ethical considerations
  • strategic research priorities, as advised by the Board of Trustees and the CAP 

Q: What is the payment schedule?

A: Payments are staged, with 45% given on receipt of a signed agreement, 45% on receipt of a satisfactory progress report, and the final 10% on receipt of a final report. Progress reports are expected periodically and reports must be approved by the IGA.

Grants that fail to begin and/or fail to supply relevant information or a fully signed agreement within 12 months of the date of the written confirmation of the award may be withdrawn. 

Q: will the IGA co-fund projects?

A: Yes, we are happy to co-fund, and often work with partners to administer and/or co-fund research grants. Recent partners have included the UK and Eire Glaucoma Society, the Royal College of Ophthalmologists, the Royal College of Nursing, the College of Optometrists and Fight for Sight. 

Q: Does the IGA accept unsolicited funding requests?

A: In exceptional circumstances and where funds allow, the IGA may consider unsolicited or ad hoc funding requests for fellowships, scholarships, awards, prizes, small research grants or joint awards with other funding bodies. 

Q: Are there any geographic constraints on research awards?

A: The lead researcher must be based in the British Isles, and if a research project is to take place outside the British Isles, it must have demonstrable benefit to the British population.  

Q: What is the IGA’s position on animal research?

A: The IGA supports the use of animals in research only when it is necessary to advance understanding of health and disease and to develop new treatments. This research only takes place where there is no alternative available. We will only support the use of animals:        

  • where no valid alternative exists
  • where regard to animal welfare is a priority for the applicant
  • where the applicant considers the possibilities to advance the refinement, reduction and replacement of animal use throughout the project.

Terms and conditions

All IGA awards are covered by the IGA terms and Conditions of Grant Aid. Download here.

National Institute for Health Research support

The IGA is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that we fund may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network. The NIHR Clinical Research Network can now support health and social care research taking place in non-NHS settings, such as studies running in care homes or hospices, or public health research taking place in schools and other community settings. Read the full policy: Eligibility Criteria for NIHR Clinical Research Network Support.

In partnership with your local R&D office, we encourage you to involve your local NIHR Clinical Research Network team in discussions as early as possible when planning your study. This will enable you to fully benefit from the support available through the NIHR Study Support Service. To find out more, please visit:

If your study involves NHS sites in England you will need to apply for Health Research Authority Approval. For guidance on submitting an application please visit: